Panacea Biotech Shares Soar 7% on Major Dengue Vaccine Trial Milestone

• Panacea Biotech shares surged 7% after completing enrolment for its Phase III Dengue vaccine trial.
• The trial for DengiAll, a tetravalent single-shot vaccine, enrolled 10,335 participants.
• Participants will be monitored for two years to assess the vaccine's efficacy and immunogenicity.
• DengiAll aims to be India's first indigenous single-dose dengue vaccine, targeting a 2027 launch.
• Dengue vaccine development is historically challenging, with past issues like Sanofi's Dengvaxia.

Why It Matters: Panacea Biotech's DengiAll vaccine completes Phase III enrolment, boosting shares and targeting a 2027 India launch.